Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript

Wedbush Securities has initiated its 'Rewind series' with a webinar reviewing key highlights from the recent United European Gastroenterology (UEGW) conference, focusing on significant updates within the Inflammatory Bowel Disease (IBD) sector. The discussion features analysis from Wedbush's healthcare equity research team, alongside insights from Dr. Marla Dubinsky of Mount Sinai, David De Vries of Tr1X Bio, and Taylor Schreiber of Shattuck Labs, providing institutional investors with a timely overview of critical developments in the biotech and healthcare space.

Analysis

Wedbush Securities has launched its "Rewind series," an initiative designed to provide institutional investors with timely analysis of key conference highlights. The inaugural session, held on October 8, focuses on significant updates from the recent United European Gastroenterology Week (UEGW) conference in Berlin, specifically within the Inflammatory Bowel Disease (IBD) sector. This new series positions Wedbush as a proactive source of specialized industry insights.

The webinar features a panel of experts, including Wedbush's healthcare equity research team, Dr. Marla Dubinsky from Mount Sinai, David De Vries of Tr1X Bio, and notably, Taylor Schreiber, CEO of Shattuck Labs (NASDAQ: STTK). The inclusion of Shattuck Labs' CEO suggests the discussions around IBD developments at UEGW may have direct implications or relevance for the company's strategic focus or pipeline.

Despite the high-profile participation and focus on a critical therapeutic area, the overall sentiment surrounding this announcement is neutral, with a very low market impact score of 0.1. This indicates that the launch of the series itself, or the initial review, is not perceived as immediately driving significant market movements for STTK or the broader healthcare sector. The value lies more in the ongoing provision of expert analysis rather than an immediate catalyst.

Key Decisions for Investors

• Monitor Shattuck Labs (STTK) for potential IBD pipeline or strategic updates that may be discussed in detail during Wedbush's "Rewind series" following the UEGW conference
• Leverage Wedbush's new "Rewind series" as a valuable source for expert analysis on key biotech and healthcare conference developments
• Acknowledge the neutral sentiment and low market impact of this specific announcement, indicating that immediate trading decisions based solely on the series launch are not warranted